Should I buy or sell Nykode Therapeutics AS stock right now?

1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Nykode Therapeutics AS in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" VACBF shares. View VACBF analyst ratings or view top-rated stocks .

How have VACBF shares performed in 2024?

Nykode Therapeutics AS's stock was trading at $1.58 at the start of the year. Since then, VACBF stock has decreased by 20.9% and is now trading at $1.25. View the best growth stocks for 2024 here .

How do I buy shares of Nykode Therapeutics AS?

Shares of VACBF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

OTCMKTS:VACBF

Nykode Therapeutics AS (VACBF) Stock Price, News & Analysis

→ He Is Giving Away Bitcoin (From Crypto Swap Profits) (Ad)

Free VACBF Stock Alerts

$1.25

0.00 (0.00%)

(As of 05/1/2024 ET)

Compare

Today's Range: $1.25
▼
$1.25
50-Day Range: $1.25
▼
$1.58
52-Week Range: $1.25
▼
$1.58

Volume: N/A
Average Volume: N/A
Market Capitalization: N/A

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: N/A

Stock Analysis Analyst Forecasts Chart Short Interest

Get Nykode Therapeutics AS alerts:

Ad Crypto Swap Profits

He Is Giving Away Bitcoin

And my special guest is willing to give you $10 in Bitcoin (BTC) if you take it seriously. Right now is a very important time to pay attention to what we are doing and what is happening. If you wait... it will be too late. This week we are holding several workshops and if you attend and pay attention my special guest is going to send you $10 in Bitcoin.

>> Register right here

About Nykode Therapeutics AS

Nykode Therapeutics AS, a clinical-stage biopharmaceutical company, discovers and develops novel immunotherapies. The company develops vaccines for the treatment cancer and infectious diseases. Its lead product candidates include VB10.NEO, a cancer neoantigen vaccine, which is in phase I/IIa clinical trial for the treatment of ,melanoma, lung, bladder, renal, head, and neck cancer; VB10.16, a therapeutic vaccine, which in phase II clinical trial for the treatment of human papilloma virus 16 induced malignancies, such as cervical cancer; and VB10. COV2, a COVID-19 vaccine candidate covers new SARS-CoV-2 variants. The company has collaboration agreements with Roche, Genentech, MSD, and Nektar Therapeutics; Adaptive Biotechnologies for T cell vaccine development; and research agreement with Regeneron. Nykode Therapeutics AS was founded in 2006 and is based in Oslo, Norway.

VACBF Stock Price History

30 days | 90 days | 365 days | Advanced Chart

VACBF Stock News Headlines

April 19, 2024 | globenewswire.com

Nykode Therapeutics Initiates Phase 2 Trial of VB10.16 in Second Line HPV16-Positive Cervical Cancer

March 21, 2024 | globenewswire.com

Nykode Therapeutics Announces Topline Conclusions Affirming Prolonged Clinical Benefits from Matured Survival Data in Phase 2 C-02 Trial in Advanced Cervical Cancer

May 2, 2024 | Crypto Swap Profits (Ad)

He Is Giving Away Bitcoin

March 19, 2024 | globenewswire.com

Nykode Therapeutics Announces Advances in the Inverse Vaccine Platform With the Potential to Treat Autoimmune Diseases

January 29, 2024 | finance.yahoo.com

Nykode Therapeutics - Quarterly report Q3 2023

See More Headlines

Receive VACBF Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Nykode Therapeutics AS and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange: OTCMKTS
Sector: Medical
Industry: Biotechnology
Sub-Industry: N/A
Current Symbol: OTCMKTS:VACBF
CUSIP: N/A
CIK: N/A
Web: nykode.com
Phone: 47-22-95-81-93
Fax: N/A
Employees: 171
Year Founded: N/A

Profitability

EPS (Most Recent Fiscal Year): N/A
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: N/A
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: N/A
Return on Assets: N/A

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: N/A
Quick Ratio: N/A

Sales & Book Value

Annual Sales: N/A
Price / Sales: N/A
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: N/A
Price / Book: N/A

Miscellaneous

Outstanding Shares: N/A
Free Float: N/A
Market Cap: N/A
Optionable: Not Optionable
Beta: N/A

5G Stocks: The Path Forward is Profitable

Click the link below and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.

Get This Free Report

Key Executives

Mr. Michael Thyring Engsig (Age 52)
Chief Executive Officer
Comp: $567k
Dr. Agnete B. Fredriksen Ph.D. (Age 47)
Chief Scientific Officer & Co-founder
Mr. Harald Gurvin (Age 49)
Chief Financial Officer
Mr. Ulrich Blaschke
Chief Technology Officer
Ms. Louise Stubbe
Chief Legal Officer
Dr. Klaus Edvardsen M.D. (Age 61)
Ph.D., Chief Research & Development Officer

Key Competitors

View All Competitors

VACBF Stock Analysis - Frequently Asked Questions

Should I buy or sell Nykode Therapeutics AS stock right now?: 1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Nykode Therapeutics AS in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" VACBF shares.
View VACBF analyst ratings or view top-rated stocks.
How have VACBF shares performed in 2024?: Nykode Therapeutics AS's stock was trading at $1.58 at the start of the year. Since then, VACBF stock has decreased by 20.9% and is now trading at $1.25.
View the best growth stocks for 2024 here.
How do I buy shares of Nykode Therapeutics AS?: Shares of VACBF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (OTCMKTS:VACBF) was last updated on 5/2/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial